Safety of a Herpes Simplex Candidate Vaccine (gD2t) With MPL and Its Efficacy to Prevent Genital Herpes Disease

Inclusion Criteria: * Between 18 and 45 years of age at the time of first vaccination * Written informed consent * Females of childbearing potential must have a negative pregnancy test at enrollment and be using an accepted method of birth control * The volunteers must have a regular sexual partner with genital herpes disease confirmed by medical history Exclusion Criteria: * Any previous history of or current clinical signs or symptoms of genital herpes disease. * Any previous vaccination against herpes simplex. * Any previous administration of MPL. * History of herpetic keratitis. * History of erythema multiforme. * Female subjects who are pregnant, lactating or planning a pregnancy before one month after the last vaccine dose. * Patient is immuno-compromised or is receiving immuno-modifying therapy of any kind. Topical corticoid therapy is allowed. * HIV positive at the time of enrollment * Clinical signs of acute or febrile illness at the time of entry into the study. * Any continuous suppressive antiviral oral therapy within the 6 months prior to entry. * Any administration of immunoglobulins during the vaccination course or within one month prior to the first vaccination. * Any vaccine administration less than one week before or after a study vaccination. * Previous known hypersensitivity to vaccination or to any component of the vaccine. * Simultaneous participation in any other clinical trial of an investigational compound. * Recent history of alcoholism or drug abuse * Recent clinical history or evidence of significant hepatic disease * Recent clinical history or evidence of renal dysfunction * Life-threatening or serious cardiac (NYHA grades III-IV), gastrointestinal, haematological or immunological disorder which, in the opinion of the investigator, would preclude entry into the study. * Inability or unwillingness to comply with the protocol or not expected to complete the study period